

MIRA INFORM REPORT

Report No. :	522590
Report Date :	02.08.2018

IDENTIFICATION DETAILS

Name :	MALLINCKRODT LLC
Registered Office :	Corporation Trust Center 1209 Orange St, Wilmington, Delaware
Country :	United States
Financials (as on) :	2017 [Summarized]
Date of Incorporation :	1867
Legal Form :	Limited Liability Company
Line of Business :	Subject manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions
No. of Employees :	5500

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	A+
------------------------	----

Credit Rating	Explanation	Rating Comments
A+	Low Risk	Business dealings permissible with low risk of default

Maximum Credit Limit :	USD 1 000 000
Status :	Good
Payment Behaviour :	Regular
Litigation :	Exist

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

ECGC Country Risk Classification List

Country Name	Previous Rating (31.12.2017)	Current Rating (01.04.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

UNITED STATES - ECONOMIC OVERVIEW

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program (TARP) in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

In December 2012, the Federal Reserve Board (Fed) announced plans to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

STATUTORY INFORMATION

Legal Name	MALLINCKRODT LLC
Trade Name	Mallinckrodt Pharmaceuticals
ID	ID
ID Details	2161269
Internal Revenue Number (IRS):	431479062
Creation Date	1867
Incorporation Date	5/19/1988
Legal Address	CORPORATION TRUST CENTER 1209 ORANGE ST, Wilmington, Delaware, USA
Operative Address	675 McDonnell Blvd. St. Louis, MO 63042 USA
Telephone	314.654.2000
Fax	NA
Legal Form	LIMITED LIABILITY COMPANY
E-Mail	NA
Registered In	DELAWARE
Website	www.mallinckrodt.com
Contact	Mark Trudeau - President and Chief Executive Officer
Staff	5500
Activity	SIC Code: 3841, Surgical and Medical Instruments and Apparatus NAICS Code: 339112, Surgical and Medical Instrument Manufacturing

BANKS

Name of Bank	Reported Amount
Bank of America	
Description	-

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

HISTORY

History

Mallinckrodt LLC was founded in 1867.

Key Developments

Mallinckrodt LLC Presents at 5th Annual Promotional Review Committee Compliance & Best Practices conference, Oct-16-2017 09:00 AM

Oct 13 17

Mallinckrodt LLC Presents at 5th Annual Promotional Review Committee Compliance & Best Practices conference, Oct-16-2017 09:00 AM. Venue: Wyndham Hamilton Park, Florham Park, New Jersey, United States. Speakers: Jessica Cirillo, Director, HEOR Acute Care Lead, Kimberly Belsky, Sr. Director, Regulatory Policy and Intelligence, Regulatory Affairs.

Intellipharma Announces Launch of Generic Seroquel XR® by Mallinckrodt

Jun 6 17

Intellipharma International Inc. announced that Mallinckrodt LLC ('Mallinckrodt'), in its capacity as the company's marketing and distribution partner, launched all strengths of the Company's generic Seroquel XR® (quetiapine fumarate extended-release tablets) in the U.S. This launch follows the recent final approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. Seroquel XR®, and the drug active quetiapine fumarate, are indicated for use in the treatment of schizophrenia and bipolar disorder. According to Symphony Health Solutions, sales in the United States for the 12 months ended April 2017 of the 50, 150, 200, 300 and 400 mg strengths of Seroquel XR® (branded and generic) were approximately U.S.\$842 million (TRx MBS Dollars, which represents projected new and refilled prescriptions representing a standardized dollar metric based on manufacturer's published catalog or list prices to wholesalers, and does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price). There can be no assurance that the Company's generic Seroquel XR® in any of the 50, 150, 200, 300 and 400 mg strengths will be successfully commercialized.

Parent Company

Mallinckrodt Pharmaceuticals Wins \$15.26 Million Federal Contract
May 27 17
Mallinckrodt Pharmaceuticals won a \$15,258,350.62 federal contract from the Defense Logistics Agency for oxycodone hydrochloride acetaminophen tablets. Mallinckrodt LLC operates as a subsidiary of :
Mallinckrodt PLC
3 Lotus Park
The Causeway
Staines-Upon-Thames, TW18 3AG
United Kingdom

PRINCIPAL ACTIVITY

General Description

Mallinckrodt LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions.

Service/Product Description

It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems.

Sales

Wholesale

Operations Area

National and International

Imports From

India, France

Employees

5500 employees

Payments With Suppliers

Regular

BRANDS

Brand

Comments

There are not informed brands

CLIENTS

Name of Client	Country	Comments
Grunenthal Colombiana S.A.	Colombia	-
LINDE ECUADOR SA	Ecuador	-
Comments	-	-

SUPPLIERS

Supplier Name	Country	Comments
Linde France	France	-
Arvee Laboratories (India) Pvt. Ltd	India	-
Govt.Of India Min.Of Finance	India	-
Comments	-	-

LOCATION

Headquarters	675 McDonnell Blvd. St. Louis, MO 63042 USA
Branches	PERRYVILLE I I I CORPORATE PARK 53 FRONTAGE ROAD, THIRD FLOOR HAMPTON, NJ, 08827 United States 2111 E GALBRAITH RD CINCINNATI, OH, 45237- 1624 United States 25 US-206 BEDMINSTER, NJ, 07921 United States

GROUP STRUCTURE AND SUBSIDIARY COMPANIES

Listed at the stock exchange	No
Capital	NA
Shareholders (%)	Mallinckrodt LLC operates as a subsidiary of : Mallinckrodt PLC 3 Lotus Park The Causeway Staines-Upon-Thames, TW18 3AG

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.



MIRA INFORM PRIVATE LIMITED
 605, Palmspring, Near D'Mart, Link Road,
 Malad (West), Mumbai - 400 064. INDIA
 Tel : 91-22-40448000 (44 lines)
 Fax : 91-22-40448045 / 40448046
 E-mail : mira@mirainform.com
 info@mirainform.com
 Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

Management	United Kingdom Mark Trudeau - President and Chief Executive Officer Matthew Harbaugh - Chief Financial Officer Frank Scholz - Chief Operations Officer No subsidiary companies were found.
Subsidiary Companies	
Related Companies	Mallinckrodt Medical, Inc. 675 McDonnell Boulevard St. Louis, MO 63134 United States Therakos, Inc. 10 North High Street West Chester, PA 19380 United States Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive Suite D Anaheim, CA 92807 United States Mallinckrodt Hospital Products Inc. 675 JAMES S MCDONNELL BLVD HAZELWOOD, MO, 63042-2379 United States

FINANCIAL INFORMATION

General Description	The company does not make its financial statements public. The following information has been provided by private sources:
Year/Currency	2017 USD
Sales	1.5B
Money Flow	Normal
IMPORT FOB DOLLAR	
Year	Amount
There are not Import Fob Dollar informed	
EXPORT FOB DOLLAR	
Year	Amount

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

There are not Export Fob Dollar informed

LEGAL FILINGS

Lawsuits

County of Clinton, Michigan v. Purdue Pharma L.P. et al
Plaintiff: County of Clinton, Michigan
Defendant: Purdue Pharma L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International PLC, Endo Health Solutions, Inc., Endo Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt PLC, Mallinckrodt LLC, Allergan PLC, Allergan Finance LLC, Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc., AmerisourceBergen Drug Corporation, Cardinal Health, Inc., McKesson Corporation, Omnicare Distribution Center LLC, Masters Pharmaceutical, Inc., CVS Health Corporation, CVS Pharmacy, Inc., Omnicare, Inc., Walgreens Boots Alliance, Inc., Walgreen Company, Rite Aid Corporation, Rite Aid of Michigan, Inc. and Costco Wholesale Corporation
Case Number: 1:2018op45889
Filed: July 27, 2018
Court: Ohio Northern District Court
Office: Cleveland Office
County: Cuyahoga
Presiding Judge: Dan Aaron Polster (MDL 2804)
Nature of Suit: Other Personal Injury
Cause of Action: 18:1962
Jury Demanded By: Plaintiff

Parish of St. John the Baptist, Louisiana v. AmerisourceBergen Drug Corporation et al
Plaintiff: Parish of St. John the Baptist, Louisiana
Defendant: AmerisourceBergen Drug Corporation, Cardinal Health Inc, McKesson Corporation, Purdue Pharma LP, Purdue Pharma Inc, The Purdue Frederick Company, Inc., Teva Pharmaceuticals Industries Ltd, Teva Pharmaceuticals, U.S.A., Inc., Cephalon, Inc., Johnson & Johnson, Janssen Pharmaceuticals Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica Inc., Noramco, Inc., Endo Health Solutions, Inc., Allergan PLC, Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc., Mallinckrodt, LLC,



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

Mallinckrodt, PLC, Insys Therapeutics, Inc., CVS Health Corp., Walgreens Boots Alliance, Inc., Wal-Mart, Inc., Morris & Dickson Co LLC, Louisiana Wholesale Drug Co., Inc. and Endo Pharmaceuticals, Inc.
Case Number: 2:2018cv07070
Filed: July 27, 2018
Court: Louisiana Eastern District Court
Office: New Orleans Office
County: St John the Baptist
Nature of Suit: Racketeer Influenced and Corrupt Organizations
Cause of Action: 18:1961
Jury Demanded By: Plaintiff

Webster Parish v. AmerisourceBergen Drug Corporation et al
Plaintiff: Webster Parish
Defendant: ALLERGAN PLC f/k/a ACTAVIS PLC, Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., AmerisourceBergen Drug Corporation, Cardinal Health, Inc, Cephalon, Inc., Endo Health Solutions, Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt LLC, Mallinckrodt PLC, McKesson Corporation, Noramco, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc., Purdue Pharma L.P., Purdue Pharma, Inc., TEVA Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., The Purdue Frederick Company, Inc., WATSON PHARMACEUTICALS, INC. n/k/a ACTAVIS, INC. and Watson Laboratories, Inc.
Case Number: 3:2018cv00720
Filed: July 27, 2018
Court: Louisiana Middle District Court
Office: Baton Rouge Office
Presiding Judge: Brian A. Jackson
Referring Judge: Erin Wilder-Doomes
Nature of Suit: Racketeer/Corrupt Organization
Cause of Action: 18:1961 Racketeering (RICO) Act
Jury Demanded By: Plaintiff

Kentucky League of Cities Insurance Services v. Purdue Pharma, L.P. et al
Plaintiff: Kentucky League of Cities Insurance Services
Defendant: Purdue Pharma, L.P., Purdue Pharma, Inc., The Purdue Frederick Company, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Johnson & Johnson,

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica Inc., Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., Allergan, PLC, Allergan Finance, LLC, Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc., Insys Therapeutics, Inc., Mallinckrodt, LLC, McKesson Corporation, Cardinal Health, Inc., Amerisource Bergen Corporation and Walgreens Boots Alliance, Inc.

Case Number: 5:2018cv00471

Filed: July 26, 2018

Court: Kentucky Eastern District Court

Office: Lexington Office

County: Fayette

Presiding Judge: Gregory F. VanTatenhove

Nature of Suit: Racketeer Influenced and Corrupt Organizations

Cause of Action: 18:1961

Jury Demanded By: None

Town of Sturbridge v. Amerisourcebergen Drug Corporation et al

Plaintiff: Town of Sturbridge

Defendant: Amerisourcebergen Drug Corporation, Cardinal Health, Inc., McKesson Corporation, Purdue Pharma L.P., Purdue Pharma, Inc., The Purdue Frederick Company, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., JANSSEN PHARMACEUTICA, INC., Noramco, Inc., Endo Health Solutions, Inc., Endo Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc., Allergan plc, Allergan Finance LLC, Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc., Mallinckrodt plc, Mallinckrodt LLC, SpecGX, LLC, Insys Therapeutics, Inc., CVS Health Corporation, Individually, H.D. Smith Wholesale Drug Co., Rite Aid Corporation, Individually, Rite Aid of Massachusetts, Inc., Walmart, Inc., Walmart Stores East, LP, Individually and Walgreen Boots Alliance, Inc., Individually

Case Number: 4:2018cv40126

Filed: July 26, 2018

Court: Massachusetts District Court

Office: Worcester Office

County: Worcester

Nature of Suit: Racketeer Influenced and Corrupt Organizations

Cause of Action: 18:1961
Jury Demanded By: Plaintiff

Town of West Boylston, Massachusetts v.
Amerisourcebergen Drug Corporation et al
Plaintiff: Town of West Boylston, Massachusetts
Defendant: AmerisourceBergen Drug Corporation,
Cardinal Health Inc., McKesson Corporation, Purdue
Pharma L.P., Purdue Pharma Inc., Purdue Frederick
Company, Inc., Teva Pharmaceutical Industries Ltd.,
Teva Pharmaceuticals USA, Inc., Cephalon Inc.,
Johnson & Johnson, Janssen Pharmaceuticals, Inc.,
Ortho-McNeil-Janssen Pharmaceuticals, Inc., Janssen
Pharmaceutica Inc., Noramco Inc, Endo Health
Solutions Inc., Endo Pharmaceuticals Inc., Par
Pharmaceutical, Inc., Par Pharmaceutical Companies,
Inc., Allergan PLC, Allergan Finance LLC, Watson
Laboratories Inc., Actavis LLC, Actavis Pharma, Inc.,
Mallinckrodt PLC, Mallinckrodt LLC, SpecGX LLC,
Insys Therapeutics Inc., CVS Health Corporation, H.D.
Smith Wholesale Drug Co., Rite Aid Corporation,
Walmart Inc., Walmart Stores East, L.P., Walgreen
Boots Alliance, Inc. and Walgreen Pharmacy Services
Midwest, LLC

Case Number: 1:2018op45858
Filed: July 25, 2018
Court: Ohio Northern District Court
Office: Cleveland Office
County: Out Of State
Presiding Judge: Dan Aaron Polster (MDL 2804)
Nature of Suit: Racketeer/Corrupt Organization
Cause of Action: 18:1961 Racketeering (RICO) Act
Jury Demanded By: Plaintiff

Eaton, County of v. Purdue Pharma, L.P. et al
Plaintiff: Eaton, County of
Defendant: Purdue Pharma, L.P., Purdue Pharma, Inc.,
The Purdue Frederick Company, Inc., Endo Health
Solutions, Inc., Endo Pharmaceuticals, Inc., Par
Pharmaceutical, Inc., Par Pharmaceutical Companies,
Inc., Janssen Pharmaceuticals, Inc., Janssen
Pharmaceutica, Inc., Noramco, Inc., Ortho-McNeil-
Janssen Pharmaceuticals, Inc., Johnson & Johnson,
Teva Pharmaceutical Industries Ltd., Teva
Pharmaceuticals USA, Inc., Cephalon, Inc., Allergan
PLC, Allergan Finance LLC, Watson Laboratories, Inc.,
Actavis LLC, Actavis Pharma, Inc., Insys Therapeutics,
Inc., Mallinckrodt PLC, Mallinckrodt LLC, SpecGx, LLC,
Cardinal Health, Inc., McKesson Corporation,

Trademarks

AmerisourceBergen Drug Corporation,
AmerisourceBergen Corporation, Walgreens Boots
Alliance, Inc., WalMart Inc., The Kroger Co., Rite Aid
Corporation, Rite Aid of Maryland, Inc. and CVS Health
Corporation

Case Number: 1:2018cv00823

Filed: July 25, 2018

Court: Michigan Western District Court

Office: Southern Division (1) Office

County: Eaton

Nature of Suit: Racketeer Influenced and Corrupt
Organizations

Cause of Action: 18:1961

Jury Demanded By: Plaintiff

AVERDOL

pharmaceutical products for the treatment of conditions
and disorders of the central nervous system

Owned by: MALLINCKRODT LLC

Serial Number: 77605315

CARES ALLIANCE

Promoting collaboration between pharmaceutical
companies, health care providers, pharmacists,
patients, and the general...

Owned by: MALLINCKRODT LLC

Serial Number: 85122197

C·A·R·E·S ALLIANCE

Promoting collaboration between pharmaceutical
companies, health care providers, pharmacists,
patients and the general public...

Owned by: MALLINCKRODT LLC

Serial Number: 85122227

PENNPAL

Providing information about disease state information
and prescription drug treatment to patients having
osteoarthritis...

Owned by: MALLINCKRODT LLC

Serial Number: 85263069

Tricarbonyl Complexes with Tridentate Chelators for
Myocardium Imaging

Publication number: 20130129620

Abstract: Chelators of the formulae (I), (II) and (III) and
tricarbonyl complexes of radioisotopes of Tc and Re
bound to them, for use in myocardial imaging.

Type: Application

Filed: January 15, 2013

Publication date: May 23, 2013

Patents Registered

Applicant: Mallinckrodt LLC
Inventor: Mallinckrodt LLC
Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging
Publication number: 20130131327
Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
Type: Application
Filed: January 15, 2013
Publication date: May 23, 2013
Applicant: Mallinckrodt LLC
Inventor: Mallinckrodt LLC

One Pot Process for Producing 6-Hydroxyl Na-Opiate
Publication number: 20130203999
Abstract: The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the nal-opiate.
Type: Application
Filed: February 8, 2013
Publication date: August 8, 2013
Applicant: MALLINCKRODT LLC
Inventor: Mallinckrodt LLC

Process for the Production of Seven-Membered Lactam Morphinans
Publication number: 20130144053
Abstract: The present invention relates to improved processes for preparing lactam morphinans. The processes generally transform keto-morphinans to seven-membered lactam morphinans using a hydroxyamine sulfonic acid reagent and proceed in high yield and with good selectivity.
Type: Application
Filed: December 5, 2012
Publication date: June 6, 2013
Applicant: Mallinckrodt LLC
Inventor: Mallinckrodt LLC

Combinational Liposome Compositions for Cancer Therapy
Publication number: 20130115273
Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an

active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Type: Application

Filed: October 31, 2012

Publication date: May 9, 2013

Applicant: MALLINCKRODT LLC

Inventor: MALLINCKRODT LLC

PROTECTIVE SHROUD FOR NUCLEAR PHARMACY GENERATORS

Publication number: 20130029073

Abstract: A protective shroud is provided for covering a radiation shield that surrounds a nuclear pharmacy generator. The radiation shield includes components having seams therebetween. The protective shroud includes a tubular body configured to contain the radiation shield, a first opening adapted for receiving the radiation shield, and a second opening for allowing access into the radiation shield.

Type: Application

Filed: September 25, 2012

Publication date: January 31, 2013

Applicant: MALLINCKRODT LLC

Inventor: MALLINCKRODT LLC

No records found.

Renewals

UCC (Uniform Commercial Code)

No records found.

OFAC Sanctions List Search

The company is not listed in the OFAC list.

SUMMARY

Summary

Founded in 1867, Mallinckrodt LLC is an organization in the Surgical and Medical Instruments Industry headquartered in St Louis, MO. The company has 5500 regular employees and generates an estimated \$1.5 billion USD in annual revenue. It operates nationally and internationally, mainly exporting to Colombia and Ecuador. It is ACTIVE in business with no negative records.

RISK INFORMATION

Debts	Controlled
Payments	Regular
Cash Flow	Normal
Suggested Credit Line	USD 1 000 000
State	Active

INTERVIEW

First Name	NA
Position	Operator
Comments	She confirmed the name of the company and the address of the headquarters and location of the company. However, she was reluctant to provide any further information.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 68.61
UK Pound	1	INR 89.93
Euro	1	INR 80.12
USD	1	INR 68.68

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	NIS
Report Prepared by :	SYL

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.